Quarterly report pursuant to Section 13 or 15(d)

Intangible Assets

v3.8.0.1
Intangible Assets
9 Months Ended
Sep. 30, 2017
Notes to Financial Statements  
Note 5 - Intangible Assets

The Company’s intangible assets consist of intellectual property and patents, mainly acquired in the acquisition of Belgian Volition (formerly ValiBio SA). The patents and intellectual property are being amortized over the assets’ estimated useful lives, which range from 8 to 20 years.

 

                September 30,  
                2017  
          Accumulated     Net Carrying  
    Cost     Amortization     Value  
    $     $     $  
                   
Patents     1,198,930       606,054       592,876  
                         
      1,198,930       606,054       592,876  
                         
                    December 31,  
                    2016  
            Accumulated     Net Carrying  
    Cost     Amortization     Value  
    $     $     $  
                         
Patents     1,085,133       482,940       602,193  
      1,085,133       482,940       602,193  

 

During the nine-month period ended September 30, 2017, and the nine-month period ended September 30, 2016, the Company recognized $65,182 and $65,313, respectively, in amortization expense.

 

The Company amortizes the long-lived assets on a straight-line basis with terms ranging from 8 to 20 years. The annual estimated amortization schedule over the next five years is as follows:

 

2017 - remaining   $ 26,321  
2018   $ 91,504  
2019   $ 91,504  
2020   $ 91,504  
2021   $ 91,504  

 

The Company reviews its long-lived assets on an annual basis, to ensure that their carrying value does not exceed their fair market value. The Company carried out such a review in accordance with ASC 360 as of December 31, 2016. The result of this review confirmed that the fair value of the patents exceeded their carrying value as of December 31, 2016.